Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease. Founded by world-renowned experts in renal disease, Walden is applying its unique, systems-based approach to address the intersection between the pathology and biology of kidney disease. Walden was launched in 2020 by ARCH Venture Partners and UCB Ventures and is headquartered in Cambridge, MA.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/07/20 | $51,000,000 | Series A |
ARCH Venture Partners UCB | undisclosed |
